Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma: A Comparison with the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma

Journal of Thoracic Oncology

Volumn 10, Issue 12, 2015, Pages 1785-1794

  Lee, Ho Yun ^a   Lee, So Won ^a   Lee, Kyung Soo ^a   Jeong, Ji Yun ^b,d   Choi, Joon Young ^b   Kwon, O Jung ^c   Song, So Hee ^a   Kim, Eun Young ^a   Kim, Jhingook ^a   Shim, Young Mog ^a  

^a Sungkyunkwan University   (South Korea)

^b Department of Pathology ^*  (South Korea)

^c Division of Respiratory and Critical Medicine   (South Korea)

^d Kyungpook National University Hospital   (South Korea)

Author keywords

Computed tomography; Ground glass opacity; Histology; Lung adenocarcinoma; Positron emission tomography; Survival

Indexed keywords

ADENOCARCINOMA IN SITU; ADULT; AGE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NOMOGRAM; OVERALL SURVIVAL; PET SCANNER; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROBABILITY; SURVIVAL TIME; TUMOR INVASION; WEDGE RESECTION; ADENOCARCINOMA; CLASSIFICATION; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR RECURRENCE; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84948084616     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000689     Document Type: Article

References (51)

1. Pirozynski M. 100 years of lung cancer. Respir Med 2006;100:2073-2084.
2. Chen F, Cole P, Bina WF. Time trend and geographic patterns of lung adenocarcinoma in the United States, 1973-2002. Cancer Epidemiol Biomarkers Prev 2007;16:2724-2729.
3. Rami-Porta R, Bolejack V, Goldstraw P. The new tumor, node, and metastasis staging system. Semin Respir Crit Care Med 2011;32:44-51.
4. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011;6:1496-1504.
5. Shedden K, Taylor JM, Enkemann SA, et al. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 2008;14:822-827.
6. Booth CM, Shepherd FA. Adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol 2006;1:180-187.
7. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
8. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: Analysis of 440 Japanese patients. J Thorac Oncol 2013;8:52-61.
9. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-664.
10. Warth A, Muley T, Meister M, et al. The novel histologic international association for the study of lung cancer/American thoracic society/European respiratory society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30:1438-1446.
11. Hung JJ, Jeng WJ, Chou TY, et al. Prognostic value of the new international association for the study of lung cancer/American thoracic society/European respiratory society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg 2013;258:1079-1086.
12. Hung JJ, Yeh YC, Jeng WJ, et al. Predictive value of the international association for the study of lung cancer/American thoracic society/European respiratory society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol 2014;32:2357-2364.
13. Sterlacci W, Savic S, Schmid T, et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. Am J Clin Pathol 2012;137:946-956.
14. Gu J, Lu C, Guo J, et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol 2013;107:474-480.
15. Yanagawa M, Tanaka Y, Kusumoto M, et al. Automated assessment of malignant degree of small peripheral adenocarcinomas using volumetric CT data: Correlation with pathologic prognostic factors. Lung Cancer 2010;70:286-294.
16. Uehara H, Tsutani Y, Okumura S, et al. Prognostic role of positron emission tomography and high-resolution computed tomography in clinical stage IA lung adenocarcinoma. Ann Thorac Surg 2013;96:1958-1965.
17. Tsutani Y, Miyata Y, Nakayama H, et al. Solid tumor size on high-resolution computed tomography and maximum standardized uptake on positron emission tomography for new clinical T descriptors with T1 lung adenocarcinoma. Ann Oncol 2013;24:2376-2381.
18. Nakayama H, Okumura S, Daisaki H, et al. Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma: A multicenter study. Cancer 2010;116:3170-3177.
19. Lee HY, Jeong JY, Lee KS, et al. Solitary pulmonary nodular lung adenocarcinoma: Correlation of histopathologic scoring and patient survival with imaging biomarkers. Radiology 2012;264:884-893.
20. Lee HY, Han J, Lee KS, et al. Lung adenocarcinoma as a solitary pulmonary nodule: Prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer 2009;66:379-385.
21. Goldstraw P. International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology. Orange Park, FL: Editorial Rx Press, 2009.
22. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th Ed. New York, NY: Springer, 2009.
23. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-1162.
24. Travis WD, BE, Müller-Hermelink HK, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC, 2004.
25. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer 2010;116:659-669.
26. Chung CK, Zaino R, Stryker JA, et al. Carcinoma of the lung: Evaluation of histological grade and factors influencing prognosis. Ann Thorac Surg 1982;33:599-604.
27. Kato H, Ichinose Y, Ohta M, et al.; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721.
28. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant navelbine international trialist association [ANITA]): A randomised controlled trial. Lancet Oncol 2006;7:719-727.
29. Van Schil PE, Asamura H, Rusch VW, et al. Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J 2012;39:478-486.
30. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials. J Clin Oncol 2013;31:992-1001.
31. Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C. Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg 2006;81:1988-1995.
32. Cha MJ, Lee HY, Lee KS, et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: Clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg 2014;147:921-928.e2.
33. Okada M, Tauchi S, Iwanaga K, et al. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas. J Thorac Cardiovasc Surg 2007;133:1448-1454.
34. Okada M, Nishio W, Sakamoto T, et al. Correlation between computed tomographic findings, bronchioloalveolar carcinoma component, and biologic behavior of small-sized lung adenocarcinomas. J Thorac Cardiovasc Surg 2004;127:857-861.
35. Ohde Y, Nagai K, Yoshida J, et al. The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma. Lung Cancer 2003;42:303-310.
36. Suzuki K, Asamura H, Kusumoto M, et al. "Early" peripheral lung cancer: Prognostic significance of ground glass opacity on thin-section computed tomographic scan. Ann Thorac Surg 2002;74:1635-1639.
37. Aoki T, Tomoda Y, Watanabe H, et al. Peripheral lung adenocarcinoma: Correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology 2001;220:803-809.
38. Nair VS, Krupitskaya Y, Gould MK. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: A systematic review. J Thorac Oncol 2009;4:1473-1479.
39. Takeda A, Sanuki N, Fujii H, et al. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy. J Thorac Oncol 2014;9:65-73.
40. Hellwig D, Gröschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:13-21.
41. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-3260.
42. Takashima S, Maruyama Y, Hasegawa M, et al. Prognostic significance of high-resolution CT findings in small peripheral adenocarcinoma of the lung: A retrospective study on 64 patients. Lung Cancer 2002;36:289-295.
43. Lee HY, Lee KS. Ground-glass opacity nodules: Histopathology, imaging evaluation, and clinical implications. J Thorac Imaging 2011;26:106-118.
44. Lee HY, Choi YL, Lee KS, et al. Pure ground-glass opacity neoplastic lung nodules: Histopathology, imaging, and management. AJR Am J Roentgenol 2014;202:W224-W233.
45. Son JY, Lee HY, Lee KS, et al. Quantitative CT analysis of pulmonary ground-glass opacity nodules for the distinction of invasive adenocarcinoma from pre-invasive or minimally invasive adenocarcinoma. PLoS One 2014;9:e104066.
46. Hoang JK, Hoagland LF, Coleman RE, et al. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008;26:1459-1464.
47. Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role. Clin Cancer Res 2007;13:3255-3263.
48. Berghmans T, Dusart M, Paesmans M, et al.; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): A systematic review and meta-analysis (MA) by the European lung cancer working party for the IASLC lung cancer staging project. J Thorac Oncol 2008;3:6-12.
49. Kadota K, Colovos C, Suzuki K, et al. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol 2012;19:3598-3605.
50. Warth A, Stenzinger A, von Brünneck AC, et al. Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas. Eur Respir J 2012;40:1221-1227.
51. Thunnissen E, Beasley MB, Borczuk AC, et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012;25:1574-1583.